Last reviewed · How we verify
Hesperidin+Diosmin combination 1000
Hesperidin and diosmin are bioflavonoids that improve venous tone and reduce capillary fragility by strengthening blood vessel walls and reducing inflammation.
Hesperidin and diosmin are bioflavonoids that improve venous tone and reduce capillary fragility by strengthening blood vessel walls and reducing inflammation. Used for Chronic venous insufficiency, Hemorrhoids, Lymphedema.
At a glance
| Generic name | Hesperidin+Diosmin combination 1000 |
|---|---|
| Sponsor | Pirogov Russian National Research Medical University |
| Drug class | Bioflavonoid combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This combination works by enhancing vascular endothelial function and reducing inflammatory mediators in the venous system. The flavonoids improve lymphatic drainage and reduce edema by decreasing capillary permeability and increasing venous return. They are commonly used to treat chronic venous insufficiency and related microcirculatory disorders.
Approved indications
- Chronic venous insufficiency
- Hemorrhoids
- Lymphedema
- Microcirculatory disorders
Common side effects
- Gastrointestinal disturbance
- Headache
- Dizziness
Key clinical trials
- Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins (NA)
- Venoactive Drug Treatment of Pelvic Venous Disorders (PHASE3)
- Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: